Spiroazacyclic compounds as monoamine receptor modulators

Details Spiroazacyclic compounds as monoamine receptor modulators Spiroazacyclic compounds as monoamine receptor modulators

2008-07-22

2008-07-22

Habte, Kahsay T (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S016000, C546S018000

Reexamination Certificate

active

11417439

ABSTRACT:
The present invention relates to optionally substituted 1-oxa-3,8-diaza-spiro[4.5]decan-2-one compounds as monoamine receptor modulators; compositions comprising the same; methods of inhibiting an activity of a monoamine receptor with said compounds; methods of treating a disease condition associated with a monoamine receptor using said compounds; and methods for identifying a subject suitable for treatment using said compounds.

REFERENCES:
patent: 3983234 (1976-09-01), Sayers
patent: 4138492 (1979-02-01), Noverola et al.
patent: 4255432 (1981-03-01), Kluge et al.
patent: 4332804 (1982-06-01), Clark
patent: 4353900 (1982-10-01), Clark
patent: 4353901 (1982-10-01), Clark
patent: 4367232 (1983-01-01), Boix-Igleasias et al.
patent: 4853394 (1989-08-01), King et al.
patent: 5025013 (1991-06-01), Barreau et al.
patent: 5214055 (1993-05-01), Peglion et al.
patent: 5216165 (1993-06-01), Mobilio et al.
patent: 5461066 (1995-10-01), Gericke et al.
patent: 5595872 (1997-01-01), Wetterau, II et al.
patent: 5621010 (1997-04-01), Sueda et al.
patent: 5707798 (1998-01-01), Brann
patent: 5795894 (1998-08-01), Shue et al.
patent: 5869488 (1999-02-01), Shue et al.
patent: 5877173 (1999-03-01), Olney et al.
patent: 5912132 (1999-06-01), Brann
patent: 5955281 (1999-09-01), Brann
patent: 6107324 (2000-08-01), Behan et al.
patent: 6140509 (2000-10-01), Behan et al.
patent: 6150393 (2000-11-01), Behan et al.
patent: 6358698 (2002-03-01), Weiner et al.
patent: 6756393 (2004-06-01), Andersson et al.
patent: 6815458 (2004-11-01), Andersson et al.
patent: 6911452 (2005-06-01), Schlienger
patent: 7022698 (2006-04-01), Hamied et al.
patent: 7041667 (2006-05-01), Armour et al.
patent: 7115634 (2006-10-01), Thurieau et al.
patent: 2004/0006081 (2004-01-01), Burrows et al.
patent: 2004/0006089 (2004-01-01), Thurieau et al.
patent: 2004/0106600 (2004-06-01), Andersson et al.
patent: 2004/0213816 (2004-10-01), Weiner et al.
patent: 2005/0014757 (2005-01-01), Andersson et al.
patent: 2005/0148018 (2005-07-01), Weiner et al.
patent: 2005/0244862 (2005-11-01), Brann
patent: 2005/0256108 (2005-11-01), Schlienger
patent: 2006/0094758 (2006-05-01), Andersson et al.
patent: 2006/0106063 (2006-05-01), Thygesen et al.
patent: 2006/0111399 (2006-05-01), Thygesen et al.
patent: 2006/0194778 (2006-08-01), Andersson et al.
patent: 2006/0194834 (2006-08-01), Andersson et al.
patent: 2006/0199794 (2006-09-01), Schlienger
patent: 2006/0199818 (2006-09-01), Andersson et al.
patent: 2006/0199842 (2006-09-01), Weiner et al.
patent: 2006/0205722 (2006-09-01), Andersson et al.
patent: 2006/0205780 (2006-09-01), Thygesen et al.
patent: 2006/0205781 (2006-09-01), Thygesen et al.
patent: 2006/0264465 (2006-11-01), Weiner et al.
patent: 2006/0264466 (2006-11-01), Weiner et al.
patent: 2006/0286610 (2006-12-01), Brann
patent: 2006/0292606 (2006-12-01), Brann
patent: 984843 (1976-03-01), None
patent: 0005318 (1979-11-01), None
patent: 0 061 333 (1982-09-01), None
patent: 0061333 (1982-09-01), None
patent: 0 379 441 (1990-07-01), None
patent: 0379441 (1990-07-01), None
patent: 0548015 (1993-06-01), None
patent: 0 260 070 (1993-08-01), None
patent: 0 260 070 (1993-08-01), None
patent: 0625507 (1994-11-01), None
patent: 2802206 (2001-06-01), None
patent: 2802206 (2001-06-01), None
patent: 157325 (1998-03-01), None
patent: WO 94/27967 (1994-12-01), None
patent: WO 94/27967 (1994-12-01), None
patent: WO 97/08166 (1997-03-01), None
patent: WO 97/11940 (1997-04-01), None
patent: WO 97/38665 (1997-10-01), None
patent: WO 97/38665 (1997-10-01), None
patent: WO 97/38984 (1997-10-01), None
patent: WO 97/38984 (1997-10-01), None
patent: WO 98/17646 (1997-10-01), None
patent: WO 98/11128 (1998-03-01), None
patent: WO 98/44921 (1998-10-01), None
patent: WO 98/50534 (1998-11-01), None
patent: WO 98/50534 (1998-11-01), None
patent: WO 99/52927 (1999-10-01), None
patent: WO 00/23076 (2000-04-01), None
patent: WO 00/56335 (2000-09-01), None
patent: WO 00/59497 (2000-10-01), None
patent: WO 00/59497 (2000-10-01), None
patent: WO 00/69810 (2000-11-01), None
patent: WO 01/44191 (2001-06-01), None
patent: WO 01/66521 (2001-09-01), None
patent: WO 01/87839 (2001-09-01), None
patent: WO 02/079186 (2002-10-01), None
patent: WO 02/079186 (2002-10-01), None
patent: WO 03/057698 (2003-07-01), None
patent: WO 03/057698 (2003-07-01), None
patent: WO 03/062206 (2003-07-01), None
patent: WO 03/062206 (2003-07-01), None
patent: WO 03/070246 (2003-08-01), None
patent: WO 03/086400 (2003-10-01), None
patent: WO 2004/000808 (2003-12-01), None
patent: WO 2004/000808 (2003-12-01), None
patent: WO 2004/009549 (2004-01-01), None
patent: WO 2004/064738 (2004-08-01), None
patent: WO 2004/064738 (2004-08-01), None
patent: WO 2004/064753 (2004-08-01), None
patent: WO 2004/072034 (2004-08-01), None
patent: WO 2005/063254 (2005-07-01), None
patent: WO 2005/112927 (2005-12-01), None
patent: WO 2006/036874 (2006-04-01), None
patent: WO 2006/036874 (2006-04-01), None
patent: WO 2006/037043 (2006-04-01), None
patent: WO 2006037043 (2006-04-01), None
patent: WO 2004/039322 (2007-05-01), None
Office Action dated Apr. 6, 2007, from U.S. Appl. No. 11/418,322, filed May 3, 2006.
Office Action dated May 8, 2007, from U.S. Appl. No. 11/417,866, filed May 3, 2006.
Notice of Allowability dated Mar. 5, 2007, from U.S. Appl. No. 10/601,070, filed Jun. 20, 2003.
Notice of Allowability dated Jun. 19, 2007, from U.S. Appl. No. 11/418,322, filed May 3, 2006.
International Preliminary Report on Patentability dated Mar. 27, 2007, for PCT/US2005/034813.
International Preliminary Report on Patentability dated Mar. 27, 2007, for PCT/US2005/034376.
Adell, et al. 2005. Strategies for producing faster acting antidepressants.Drug Discovery Today. 10(8):578-585.
Akin, et al. 2004. Decreased serotonin 5-HT2Areceptor-stimulated phosphoinositide signaling in fibroblasts from melancholic depressed patients.Neuropsychopharmacology. 29:2081-2087.
Alvisi, N. 1892. Sulla formazione di derivati pirazolici dalle dicloridrine e dalla tribromidrina della glicerina ordinaria,Gazz. Chem. Ital. 22:158-168.
Archibald, et al., 1974 “Benzamidopiperdines. 2. Heterocyclic Compounds Related to Indoramin”J. Medicinal Chemistry, 17(7):736-739.
Archibald, et al., 1974 “Benzamidopiperdines. 3. Heterocyclic Compounds Related to Indoramin” J. Medicinal Chemistry, 17(7):-739-744.
Archibald, et al., 1974 “1,4-Bis-(2-indol-3-ylethyl)piperdines” J. Medicinal Chemistry, 17(7):-745-747.
Bassus, et al. 1974. Psychotropes potentiels. X. Synthése de butyrophénones á cycle pipéridine-spiro-tétrahydrooaxazinone douées d'activité neuroleptique.Eur. J. Med. Chem.—Chimica Therapeutica, 9(4):416-423.
Blier, et al. 2005. Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety.J. Clin. Psychiatry. 66(suppl 8):30-40.
Chemical Abstracts, 73:25305. Benke, et al. 1970.
Ermakov, et al. 1981. Use of Mass spectrometry in structural and stereochemical studies.Chemistry of Heterocyclic Compounds, 1:72-77.
Finar, et al. 1954. The preparation and properties of some derivatives of 1-phenylpyrazole,J. Chem. Soc., pp. 2293-2298.
Gillman, P. K. 2005. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.British Journal of Anaesthesia, 95(4):434-441.
Irikura et al., 1971 “A New Anticulcer Agents. 1. Synthesis and Biological Activities of 1-Acyl-2-,-3-, -4-substituted Benzamidopiperdines” J. Medicinal Chemistry 14(4): 357-361.
Kanayama, et al. 2005. New treatment of lumbar disc herniation involving 5-hydroxytryptamine2Areceptor inhibitor: A randomized controlled trial.J. Neurosurg: Spine, 2:441-446.
Marek, et al. 2003. Synergistic action of 5-HT2Aantagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders.Neuropsychopharmacology, 28:402-412.
Marek, et al. 2005. The selective 5-HT2Areceptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine.Neuropsychopharmacology, 30:2205-2215.
Ogawa, et al. 2005. Effects of R-102444 and its active m

Affiliated with

Also associated with

Rating

Spiroazacyclic compounds as monoamine receptor modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Spiroazacyclic compounds as monoamine receptor modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Spiroazacyclic compounds as monoamine receptor modulators will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3923746